🟢 MetaVia is trading 6.9% up in pre-market with no clear catalyst identified

MetaVia is trading 6.9% up at $1.55 in pre-market on October 13, 2026, with no clear company-specific catalyst identified.

• Shares gained 2.84% in the October 12 session.
• MetaVia’s investor-relations page lists September 9 preclinical findings for DA-1726 as its latest press release; no October 13 announcement appears there.
• Broader markets are mixed, and available evidence does not establish a market-wide reason for the move.